SRR8518350
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.620
- IL6_JAK_STAT3_SIGNALING+0.560
- INFLAMMATORY_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.550
- COMPLEMENT+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- INTERFERON_GAMMA_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.450
- IL2_STAT5_SIGNALING+0.430
- KRAS_SIGNALING_UP+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- MYC_TARGETS_V1-0.480
- E2F_TARGETS-0.430
- G2M_CHECKPOINT-0.380
- ESTROGEN_RESPONSE_EARLY-0.310
- ESTROGEN_RESPONSE_LATE-0.290
- DNA_REPAIR-0.230
- GLYCOLYSIS-0.230
- KRAS_SIGNALING_DN-0.230
- PEROXISOME-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613803 | — | D | 0.903 |
| 2 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.898 |
| 3 | SRR8518195 | — | A | 0.895 |
| 4 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.886 |
| 5 | SRR8518216 | — | D | 0.883 |
| 6 | 6bf9821d-da67-470f-9650-69d05b056166 | — | — | 0.883 |
| 7 | TCGA-E2-A1IH-01A-11R-A13Q-07 | — | A | 0.883 |
| 8 | X038167c2.c7d9.47a2.9172.1cfe391c8131 | — | cohortMD2 | 0.882 |
| 9 | TCGA-05-4417-01A-22R-1858-07 | — | cohortA3 | 0.879 |
| 10 | f26d1599-6e75-4c0d-8b40-c7e45fe9da76 | — | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.620 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| COMPLEMENT | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |